MGC Pharmaceuticals Limited Publication of MGC Pharma Glioblastoma research (4086I)
December 02 2022 - 1:00AM
UK Regulatory
TIDMMXC
RNS Number : 4086I
MGC Pharmaceuticals Limited
02 December 2022
MGC Pharmaceuticals Ltd.
MDPI publish peer reviewed academic paper on MGC Pharma research
collaboration on the cytotoxic effects of Cannabidiol and
Cannabigerol on Glioblastoma stem cells
2 December 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a
European based pharmaceutical company specialising in the
production and development of plant inspired medicines, has had a
peer reviewed academic paper entitled 'The Cytotoxic Effects of
Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly
Involve GPR55 and TRPV1 Signalling' published by MDPI.
MDPI is the largest open access publisher of peer reviewed
academic journals, publishing nearly 400 open access journals and
the fifth largest publisher overall in terms of journal paper
output. The article has been published as a Molecular Cancer
Biology research paper.
The glioblastoma research in the publication is a collaboration
between MGC Pharma and the National Institute of Biology, a leading
research university in Slovenia [1] .
The research paper tests Cannabidiol (CBD) and Cannabigerol
(CBG) extracts provided by MGC Pharmaceuticals, and their impact on
Glioblastoma cells. The study finds that GPR55 and TRPV1 receptors
are the best targets for the antagonistic cannabinoids CBD and CBG
(in an optimised mixture) to eliminate Glioblastoma (GBM) stem
cells.
This approach avoids using psychoactive tetrahydrocannabinol
(THC), which is potentially harmful, particularly in older GBM
patients, and should be further tested in animal experiments and
clinical trials.
Glioblastoma is a fast growing and aggressive form of cancer,
usually starting in the brain. Currently only 5-10% of glioblastoma
patients live beyond five years following diagnosis [2] .
The article is open access and can be accessed at the following
URL:
https://www.mdpi.com/2072-6694/14/23/5918/pdf
--Ends--
Authorised for release by the Managing Director, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer David Lim
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.eu info@mgcpharma.eu
UK Financial and Corporate UK Broker
Advisor Turner Pope
Hannam & Partners Andy Thacker
Rupert Fane / Nilesh Patel +44 203 657 0050
+44 7810 056 104 info@turnerpope.com
rf@hannam.partners / nilesh@hannam.partners
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
bio-pharma company, focused on developing and supplying accessible
and ethically produced plant inspired medicines, combining in-house
research with innovative technologies, with the goal of finding or
producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant inspired medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant inspired medicines,
to be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
[1] Refer ASX announcement on 16 June 2022 titled "Successful
Glioblastoma Pre-clinical Trial Results"
[2]
https://www.mdanderson.org/cancerwise/10-year-glioblastoma-brain-tumor-survivor--get-busy-living.h00-159303045.html
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZMGZVZZGZZG
(END) Dow Jones Newswires
December 02, 2022 02:00 ET (07:00 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From May 2023 to May 2024